Last updated July 12, 2026
Key finding
Hazard ratio for risk of the composite HF outcome with oral semaglutide vs placebo was 0.78 (95% CI, 0.63-0.96).
This study evaluated the effect of oral semaglutide on heart failure events in patients with type 2 diabetes, finding a reduced risk of composite heart failure outcomes compared to placebo.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Low Risk
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the effect of oral semaglutide on heart failure events in patients with type 2 diabetes, finding a reduced risk of composite heart failure outcomes compared to placebo.
These findings are significant as they suggest that oral semaglutide could be an effective treatment option for reducing heart failure risk in patients with type 2 diabetes, a population already at increased risk for cardiovascular complications. This could lead to improved management strategies for diabetes and heart health.
Study design limited to a specific population of type 2 diabetes patients. Effectiveness of oral semaglutide in broader populations remains unclear. Potential unmeasured confounders may affect the results.
Published in
Publication details and source links for this paper.
Rodica P, Søren R, John ED, et al. Effect of Oral Semaglutide on Heart Failure Events in Patients with Type 2 Diabetes. JAMA Internal Medicine. 2026;186(4):426-436. doi:10.1001/jamainternmed.2025.7774
Oral semaglutide reduced the risk of composite heart failure outcomes with a hazard ratio of 0.78 (p=0.03).
The risk of major adverse cardiovascular events was lower with oral semaglutide (hazard ratio 0.83, p=0.05).
No significant differences were found in hypoglycemia or hyperglycemia events between the treatment and placebo groups.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Semaglutide and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization), Hyperglycemia events, Hypoglycemia events, and 1 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
4
Evidence pairs
175
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Follow evidence
Evidence topic
Follow evidence
Core evidence
The primary outcomes reported in this study.
Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Cardiovascular Outcomes, GLP-1 Receptor Agonists and Hypoglycemia.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Cardiovascular Outcomes
Measures Cardiovascular Outcomes as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring Hypoglycemia
Measures Hypoglycemia as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in the evidence archive.
7 results
2 results
7 results
7 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists may improve Cardiovascular Outcomes.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Hypoglycemia.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Hypoglycemia events
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.
Limitations
Current evidence does not show a clear benefit of Semaglutide for Hyperglycemia events.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Hyperglycemia events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Semaglutide for Serious SAEs.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Serious SAEs
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Follow the topics this study contributes to.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
